Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam hemodynamic effects in children with congenital heart disease undergoing cardiac catheterization
ChiCTR2400084993Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in Cardiovascular Malformation (CVM), sponsored by Shanghai Children's Medical Center. Primary endpoint: Change in pulmonary vascular resistance. Planned start May 2024; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on ChiCTR2400084993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084993.